-
Cirrhosis-related parkinsonism may represent a unique, consistent, and common subset of acquired hepatocerebral degeneration, whose features are permanent and entirely different from acute hepatic encephalopathy episodes.
-
Aripiprazole is a new antipsychotic agent approved for the treatment of schizophrenia. This atypical agent is a quinolinone that has partial agonist activity at dopamine D2 receptors. The drug will be marketed as being better tolerated and safer than other atypical agents, as well as being dosed once a day.
-
Increase in Blood Glucose Concentration During Antihypertensive Treatment as a Predictor of Myocardial Infarction; Adverse Drug Events in Ambulatory Care; Prevention of Hip Fracture by External Hip Protectors
-
-
The diagnosis and management of patients with manifestations of drug-induced cardiotoxicity is challenging for even the most experienced emergency physician. The following report reviews the pathophysiology and clinical manifestations of cardiotoxins to provide the front-line practitioners with evidence-based protocols for managing patients with life-threatening toxicity.
-
-
Child abuse can be difficult to recognize, especially in the often chaotic environment of the emergency department. As the leaders of the community and medical safety net that is the ED, emergency physicians play a unique role in detecting, treating, and preventing child abuse. This issue of Emergency Medicine Specialty Reports provides an update on the patterns, diagnosis, and treatment of physical child abuse injuries.
-
A new oral direct thrombin inhibitorximelagatran (Exanata; Astra-Zeneca)steals the stage at this years American College of Cardiology 52nd Scientific Session in Chicago.
-
Cerebral venous thrombosis (CVT) is a stroke syndrome characterized by headache, seizures, and hemorrhagic infarction.
-
Intravenous immunoglobulin (IVIG) is an expensive but powerful and useful therapeutic tool in the neurologists armamentarium. Guillain-Barré syndrome, chronic inflammatory demyelinating polyneuropathy, multifocal motor neuropathy, Lambert-Eaton myasthenic syndrome, and dermatomyositis have all been shown, in controlled clinical trials, to benefit from IVIG.
